NR4A1 and breast cancer: In hormone receptor-positive patients, 5 years of TAM treatment decreased the 5-y and 10-y breast cancer recurrence rates from 26.1 and 37.7% to 15.4% and 24.8%, respectively; however, the treatment could not decrease the recurrence rates in hormone receptor-negative patients [25].